Attendance at American Thoracic Society Congress

Reach

19 May 2025

Nuformix plc

("Nuformix" or the "Company")

Attendance at the American Thoracic Society Congress 2025 and presentation of NXP002 data

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce, its attendance at the American Thoracic Society Congress, taking place in San Francisco, USA, from 18 to 21 May 2025.

The positive results from the recent analysis of data from studies of NXP002 in a precision-cut lung slice ("PCLS") disease models using tissue from IPF and autoimmune ILD patients will be presented on 21 May within the Wednesday morning session titled "Drug Discovery and Development in IPF: Challenges and Opportunities".

Dr Dan Gooding, Executive Director, Nuformix, said: "We are delighted to be attending the ATS congress in San Francisco. We will have the opportunity to progress discussions with potential licensing and development partners and showcase the positive results from our recent analysis of NXP002's performance in tissue from multiple IPF and autoimmune ILD patients. This follows the receipt of confirmation of eligibility for Orphan Drug Designation in IPF from the EMA. I look forward to providing further updates in due course as appropriate."

Enquiries:

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

About IPF

IPF is a chronic lung disease characterised by progressive tissue scarring that prevents proper lung function. It is a progressive, fatal, age-associated lung disease affecting approximately three out of every one hundred thousand people in Europe. IPF typically presents in adults 65 or older and is usually fatal within two to five years after diagnosis.